Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents

BACKGROUND: The survival benefit of combination antifungal therapy for invasive mucormycosis (IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT) is not well defined. METHODS: This multicenter, retrospective study included HM and HCT recipients with proven or pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Matthew A, Molina, Kyle C, Gutman, Jonathan A, Scherger, Sias, Lum, Jessica M, Mossad, Sherif B, Burgess, Mary, Cheng, Matthew P, Chuang, Sally T, Jacobs, Samantha E, Melendez, Dante P, Shah, Dimpy P, Zimmer, Andrea, Sohail, M Rizwan, Syed, Sadia, Walker, Randall C, Poeschla, Eric M, Abidi, Maheen Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863870/
https://www.ncbi.nlm.nih.gov/pubmed/33575424
http://dx.doi.org/10.1093/ofid/ofaa646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863870/
https://www.ncbi.nlm.nih.gov/pubmed/33575424
http://dx.doi.org/10.1093/ofid/ofaa646

Ejemplares similares